Meta Biomed Balance Sheet Health
Financial Health criteria checks 5/6
Meta Biomed has a total shareholder equity of ₩78.3B and total debt of ₩64.3B, which brings its debt-to-equity ratio to 82.1%. Its total assets and total liabilities are ₩163.8B and ₩85.4B respectively. Meta Biomed's EBIT is ₩12.4B making its interest coverage ratio 6. It has cash and short-term investments of ₩43.0B.
Key information
82.1%
Debt to equity ratio
₩64.34b
Debt
| Interest coverage ratio | 6x |
| Cash | ₩43.01b |
| Equity | ₩78.33b |
| Total liabilities | ₩85.44b |
| Total assets | ₩163.78b |
Recent financial health updates
Recent updates
Earnings Tell The Story For Meta Biomed Co., Ltd. (KOSDAQ:059210) As Its Stock Soars 30%
Feb 26
Here's How We Evaluate Meta Biomed Co., Ltd.'s (KOSDAQ:059210) Dividend
Apr 11Meta Biomed's (KOSDAQ:059210) Stock Price Has Reduced 58% In The Past Five Years
Mar 14Are Meta Biomed's (KOSDAQ:059210) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Feb 21Can Meta Biomed (KOSDAQ:059210) Continue To Grow Its Returns On Capital?
Feb 03
Is Meta Biomed (KOSDAQ:059210) A Risky Investment?
Jan 13Here's Why I Think Meta Biomed (KOSDAQ:059210) Is An Interesting Stock
Dec 26Meta Biomed (KOSDAQ:059210) Share Prices Have Dropped 22% In The Last Five Years
Dec 08Meta Biomed Co., Ltd.'s (KOSDAQ:059210) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
Nov 20Financial Position Analysis
Short Term Liabilities: A059210's short term assets (₩76.9B) exceed its short term liabilities (₩54.8B).
Long Term Liabilities: A059210's short term assets (₩76.9B) exceed its long term liabilities (₩30.7B).
Debt to Equity History and Analysis
Debt Level: A059210's net debt to equity ratio (27.2%) is considered satisfactory.
Reducing Debt: A059210's debt to equity ratio has increased from 72.4% to 82.1% over the past 5 years.
Debt Coverage: A059210's debt is well covered by operating cash flow (23.5%).
Interest Coverage: A059210's interest payments on its debt are well covered by EBIT (6x coverage).